Skip Navigation

Cardiovascular Research 2000 48(1):158-167; doi:10.1016/S0008-6363(00)00169-3
© 2000 by European Society of Cardiology
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Babaei, S.
Right arrow Articles by Stewart, D. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Babaei, S.
Right arrow Articles by Stewart, D. J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 2000, European Society of Cardiology

Blockade of endothelin receptors markedly reduces atherosclerosis in LDL receptor deficient mice: role of endothelin in macrophage foam cell formation

Saeid Babaeia,b, Pierre Picard, Amir Ravandia, Juan Carlos Mongea, Tony C. Leea, Peter Cernacekc and Duncan J. Stewarta,b,*

aDivision of Cardiology, Terrence Donnelly Heart Center, St. Michael's Hospital, 30 Bond Street, Toronto, Ontario, Canada, M5B 1W8
bDepartments of Medicine and of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada
cMontreal Heart Institute, Department of Laboratory Medicine, Montreal, Quebec, Canada

* Corresponding author. Tel.: +1-416-864-5724; fax: +1-416-864-5419 stewartd{at}smh.toronto.on.ca

Objective: We evaluated the direct effects of long-term blockade of ETA and ETB receptors using a mixed endothelin (ET) receptor antagonist, LU224332, in the low density lipoprotein receptor (LDL-R) knockout mouse model of atherosclerosis. Methods: Four groups of LDL-R deficient mice were studied: control mice fed normal chow (group I); mice fed a high cholesterol (HC, 1.25%) diet alone (group II), HC fed animals treated with LU224332 (group III); and mice fed normal chow treated with the LU compound (group IV). All treatments were continued for 8 weeks at which time the animals were sacrificed and the aortae were removed and stained with oil red O. Atherosclerotic area (AA) was determined by quantitative morphometry and normalized relative to total aortic area (TA). Results: Cholesterol feeding resulted in a marked increased in total plasma cholesterol (~15 fold) and widespread aortic atherosclerosis (AA/TA: group I: 0.013±0.007; group II: 0.33±0.11; P<0.001). Atherosclerotic lesions were characterized by immunohistochemistry as consisting mainly of macrophages which also showed high levels of ET-1 expression. Treatment with ET antagonist significantly reduced the development of atherosclerosis (AA/TA: group III: 0.19±0.07, P<0.01 vs. group II), without altering plasma cholesterol levels and blood pressure. The direct effect of LU224332 on macrophage activation and foam-cell formation was determined in vitro using a human macrophage cell line, THP-1. Treatment of the THP-1 cells with LU224332 significantly reduced cholesterol ester and triacylglycerol accumulation and foam-cell formation on exposure to oxidized LDL (P<0.01 and P<0.05, respectively). Conclusion: We conclude that a nonselective ET receptor antagonist substantially inhibited the development of atherosclerosis in a genetic model of hyperlipidemia, possibly by inhibiting macrophage foam-cell formation, suggesting a role for these agents in the treatment and prevention of atherosclerotic vascular disease.

KEYWORDS Atherosclerosis; Cholesterol; Endothelins; Macrophages; Receptors


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 HypertensionHome page
N. Dhaun, J. Goddard, D. E. Kohan, D. M. Pollock, E. L. Schiffrin, and D. J. Webb
Role of Endothelin-1 in Clinical Hypertension: 20 Years On
Hypertension, September 1, 2008; 52(3): 452 - 459.
[Full Text] [PDF]

Home page
 Cardiovasc ResHome page
F. Bohm and J. Pernow
The importance of endothelin-1 for vascular dysfunction in cardiovascular disease
Cardiovasc Res, October 1, 2007; 76(1): 8 - 18.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
G. S. Hassan, T. M. Williams, P. G. Frank, and M. P. Lisanti
Caveolin-1-deficient aortic smooth muscle cells show cell autonomous abnormalities in proliferation, migration, and endothelin-based signal transduction
Am J Physiol Heart Circ Physiol, June 1, 2006; 290(6): H2393 - H2401.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. ProteomicsHome page
E. M. Fach, L.-A. Garulacan, J. Gao, Q. Xiao, S. M. Storm, Y. P. Dubaquie, S. A. Hefta, and G. J. Opiteck
In Vitro Biomarker Discovery for Atherosclerosis by Proteomics
Mol. Cell. Proteomics, December 1, 2004; 3(12): 1200 - 1210.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
L. L. Yang, R. Gros, M. G. Kabir, A. Sadi, A. I. Gotlieb, M. Husain, and D. J. Stewart
Conditional Cardiac Overexpression of Endothelin-1 Induces Inflammation and Dilated Cardiomyopathy in Mice
Circulation, January 20, 2004; 109(2): 255 - 261.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
P.O Bonetti, L.O Lerman, C Napoli, and A Lerman
Statin effects beyond lipid lowering--are they clinically relevant?
Eur. Heart J., February 1, 2003; 24(3): 225 - 248.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.